心衰1号方治疗高血压

发布时间：2018-05-14 17:37

本文选题：慢性心力衰竭 + 高血压病　；参考：《湖北中医药大学学报》2018年02期

【摘要】：目的观察心衰1号方对高血压病、糖尿病、冠心病并发慢性心衰(阳虚水停、血瘀络阻证)患者的临床疗效。方法将我院120例患者分成治疗组和对照组,每组各60例。治疗组给予西医常规治疗联合心衰1号方治疗,对照组给予西医常规治疗联合芪苈强心胶囊治疗,疗程均为4周。比较两组间纽约心脏病协会(NYHA)心功能分级、中医证候积分、心衰体征积分、左室射血分数(LVEF)、B型脑钠肽(BNP)、生活质量评价、住院时间及不良反应发生率。结果对照组总有效率(73.33%)低于治疗组(88.33%),差异有统计学意义(P0.05);与对照组比较,治疗组治疗后中医证候积分、心衰体征积分较低,BNP水平较低,生活质量评分较低,住院时间较短,差异有统计学意义(P0.05)。治疗后,两组LVEF均有明显的改善(P0.05),改善程度差异无统计学意义(P0.05)。两组不良反应发生率差异无统计学意义(P0.05)。结论心衰1号方治疗高血压病、糖尿病、冠心病并发慢性心衰(阳虚水停、血瘀络阻证)的临床疗效较好,能够有效改善患者心功能,改善患者临床症状及生活质量,降低BNP水平,升高左室射血分数(LVEF)水平,安全性良好。
[Abstract]:Objective to observe the clinical effect of Heart failure Formula No. 1 on patients with hypertension, diabetes and coronary heart disease complicated with chronic heart failure (Yang deficiency and water stagnation, blood stasis and collaterals obstruction). Methods 120 patients in our hospital were divided into treatment group and control group with 60 cases in each group. The treatment group was treated with routine western medicine combined with heart failure recipe No. 1, the control group was treated with traditional western medicine combined with Qiliqiangxin capsule, the course of treatment was 4 weeks. The cardiac function grading, TCM syndromes score, heart failure sign score, left ventricular ejection fraction (LVEF) B type brain natriuretic peptide (BNPP), quality of life (QOL), hospital stay and incidence of adverse reactions were compared between the two groups. Results the total effective rate of the control group (73.33) was lower than that of the treatment group (88.33%), and the difference was statistically significant (P 0.05), compared with the control group, the scores of TCM syndromes, signs of heart failure and BNP were lower, the quality of life score was lower, and the hospitalization time was shorter in the treatment group than in the control group. The difference was statistically significant (P 0.05). After treatment, LVEF in both groups was significantly improved (P 0.05), and there was no significant difference in the degree of improvement between the two groups (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion the clinical effect of Heart failure No. 1 prescription in treating hypertension, diabetes mellitus and coronary heart disease complicated with chronic heart failure (Yang deficiency and water stopping, blood stasis and collaterals blocking) is better. It can effectively improve the heart function of the patients, improve the clinical symptoms and quality of life of the patients. It is safe to reduce BNP level and increase left ventricular ejection fraction (LVEF) level.
【作者单位】：中国中医科学院广安门医院南区内科
【基金】：北京市中医药科技发展资金项目(项目编号:JJ2012-01)
【分类号】：R259

【相似文献】